No Data
No Data
No Data
No Data
No Data
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
GlobeNewswireDec 16, 2023 05:15
HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (OTC:ARDS) with a Buy and maintains $2 price target.
BenzingaNov 6, 2023 20:05
Promising Developments and Value Proposition: A Buy Rating Analysis of Aridis Pharmaceuticals
TipRanksNov 6, 2023 19:33
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
Aridis Pharmaceuticals Q3 EPS $0.00 Up From $(0.47) YoY, Sales $417.00K Up From $399.00K YoY
BenzingaNov 4, 2023 04:16
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
Aridis Pharmaceuticals Price Target Cut to $2.00/Share From $10.00 by HC Wainwright & Co.
Dow JonesOct 21, 2023 02:04
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Aridis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesOct 21, 2023 02:04
No Data
No Data